| meta-analysis | Q815382 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Roger S McIntyre | Q88039086 |
| Glenda MacQueen | Q104433097 | ||
| Roumen Milev | Q42317690 | ||
| Raymond W. Lam | Q42883552 | ||
| Rudolf Uher | Q43273047 | ||
| Pierre U. Blier | Q46045677 | ||
| Fabrice Jollant | Q56748302 | ||
| Sidney H. Kennedy | Q59560583 | ||
| P2093 | author name string | Daniel J Müller | |
| Mehrul Hasnain | |||
| Sagar V Parikh | |||
| Venkat Bhat | |||
| CANMAT Depression Work Group | |||
| Arun V Ravindran | |||
| Diane McIntosh | |||
| Anthony J Levitt | |||
| Shane J McInerney | |||
| S Valérie Tourjman | |||
| Norma L Pearson | |||
| P2860 | cites work | A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression | Q38234664 |
| QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review | Q38244346 | ||
| A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy: efficacy and tolerability | Q38356541 | ||
| Is pindolol augmentation effective in depressed patients resistant to selective serotonin reuptake inhibitors? A systematic review and meta-analysis | Q38358559 | ||
| Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report | Q38385460 | ||
| Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report | Q38388239 | ||
| Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. | Q38391914 | ||
| Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. | Q38405396 | ||
| Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. | Q38405403 | ||
| The use of ketamine as an antidepressant: a systematic review and meta-analysis | Q38408563 | ||
| Ketamine safety and tolerability in clinical trials for treatment-resistant depression | Q38422947 | ||
| A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram | Q38444868 | ||
| A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder | Q38446302 | ||
| Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants | Q38570635 | ||
| Summary of findings from the FDA regulatory science forum on measuring sexual dysfunction in depression trials | Q38579685 | ||
| Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial | Q84884469 | ||
| Withdrawal of generic budeprion for nonbioequivalence | Q85631225 | ||
| Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration | Q21092366 | ||
| Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved | Q21129279 | ||
| Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model | Q21134108 | ||
| Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes | Q21144599 | ||
| Pharmacological treatment for psychotic depression | Q24188322 | ||
| Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia | Q24201220 | ||
| Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome | Q24201799 | ||
| Second-generation antipsychotics for major depressive disorder and dysthymia | Q24235667 | ||
| Escitalopram versus other antidepressive agents for depression | Q24241065 | ||
| A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder | Q24602988 | ||
| Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine | Q24612175 | ||
| Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration | Q24653558 | ||
| The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials | Q26799627 | ||
| Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis | Q27022217 | ||
| Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy | Q28083651 | ||
| Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials | Q28088645 | ||
| Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression--a systematic review | Q28240782 | ||
| Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs | Q28259477 | ||
| A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report | Q28261272 | ||
| Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression | Q28550946 | ||
| A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state | Q28730355 | ||
| Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice | Q29614979 | ||
| Assessing efficacy/effectiveness and safety/tolerability profiles of adjunctive pramipexole in bipolar depression: acute versus long-term data | Q30670866 | ||
| The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research | Q33622133 | ||
| Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder | Q34010693 | ||
| How much do we know about the functional effectiveness of interventions for depression? A systematic review | Q38582094 | ||
| Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis | Q38584890 | ||
| Pramipexole augmentation in treatment-resistant major depressive disorder | Q39301010 | ||
| Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder | Q39441964 | ||
| Antidepressant nonadherence in routine clinical settings determined from discarded blood samples | Q40268238 | ||
| Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database | Q40828138 | ||
| Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression: a meta-analysis | Q41071836 | ||
| Duration of initial antidepressant treatment and subsequent relapse of major depression | Q41696333 | ||
| An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression | Q42614882 | ||
| Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors | Q42638301 | ||
| Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. | Q43292973 | ||
| Combination antidepressant therapy for major depressive disorder: speed and probability of remission | Q43681255 | ||
| Do atypical features affect outcome in depressed outpatients treated with citalopram? | Q44075173 | ||
| Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. | Q44142664 | ||
| Early switch strategy in patients with major depressive disorder: a double-blind, randomized study | Q44198094 | ||
| Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. | Q45208467 | ||
| STAR*D: revising conventional wisdom. | Q45931500 | ||
| Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation | Q46062036 | ||
| Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression | Q46104577 | ||
| Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. | Q46825728 | ||
| Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches | Q46963926 | ||
| Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial | Q47725364 | ||
| Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study | Q48070817 | ||
| Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study | Q48082082 | ||
| Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder | Q48083562 | ||
| Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent | Q48094257 | ||
| FINISH: remembering the discontinuation syndrome. Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances, and Hyperarousal (anxiety/agitation) | Q48795413 | ||
| Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. | Q48878233 | ||
| Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials | Q48899934 | ||
| Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care. | Q51905221 | ||
| Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. | Q55052151 | ||
| The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid conditions | Q83390109 | ||
| Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis | Q34029684 | ||
| A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder | Q34031897 | ||
| Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review | Q34043285 | ||
| Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. | Q34088016 | ||
| Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis | Q34132829 | ||
| A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults | Q34172150 | ||
| Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis | Q34172837 | ||
| Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies. | Q34214948 | ||
| Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant | Q34219738 | ||
| Comparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review. | Q34254323 | ||
| Relationship between use of antidepressants and risk of fractures: a meta-analysis | Q34277620 | ||
| Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis | Q34298760 | ||
| A review of current evidence for vilazodone in major depressive disorder | Q34338647 | ||
| Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis | Q34372615 | ||
| Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression | Q34381557 | ||
| Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials | Q34391325 | ||
| Efficacy and acceptability of acute treatments for persistent depressive disorder: a network meta-analysis | Q34399289 | ||
| Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug Administration | Q34414494 | ||
| A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder | Q34442400 | ||
| The role of ketamine in treatment-resistant depression: a systematic review | Q34449588 | ||
| Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis | Q34473982 | ||
| A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder | Q34637400 | ||
| Repeated S-ketamine infusions in therapy resistant depression: a case series | Q34654747 | ||
| Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: a double-blind, placebo-controlled and randomized study. | Q34659646 | ||
| Rational use of generic psychotropic drugs | Q34688387 | ||
| Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials | Q34997918 | ||
| Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis | Q35066804 | ||
| Comparative efficacy and risk of harms of immediate- versus extended-release second-generation antidepressants: a systematic review with network meta-analysis | Q35162633 | ||
| Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder | Q35536869 | ||
| Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials | Q35544278 | ||
| Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings | Q35708089 | ||
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors | Q35883249 | ||
| A Randomized, Double-blind, Placebo-controlled Trial of Celecoxib Augmentation of Sertraline in Treatment of Drug-naive Depressed Women: A Pilot Study | Q35897912 | ||
| Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. | Q36007894 | ||
| Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis | Q36588685 | ||
| Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods | Q36795521 | ||
| A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder | Q36821817 | ||
| Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study | Q36832408 | ||
| Evaluation of networks of randomized trials | Q36966424 | ||
| Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release | Q36995148 | ||
| Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies | Q37071328 | ||
| Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Introduction and Methods | Q37197203 | ||
| Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly. | Q37197207 | ||
| Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 2. Psychological Treatments. | Q37197221 | ||
| Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments. | Q37197224 | ||
| Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options | Q37612442 | ||
| A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder | Q37651165 | ||
| Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder | Q37705738 | ||
| Genes, environment, and individual differences in responding to treatment for depression | Q37883317 | ||
| A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. | Q37910340 | ||
| Clinically significant drug interactions with newer antidepressants | Q37968621 | ||
| Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? | Q37979497 | ||
| The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. | Q37981162 | ||
| The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. | Q37981163 | ||
| The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders. | Q37981164 | ||
| The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid personality disorders | Q37981165 | ||
| The CANMAT task force recommendations for the management of patients with mood disorders and comorbid medical conditions: diagnostic, assessment, and treatment principles | Q37981168 | ||
| The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. | Q37981169 | ||
| Emerging drugs for major depressive disorder | Q37984619 | ||
| Management of treatment-resistant depression | Q37988720 | ||
| Managing medical and psychiatric comorbidity in individuals with major depressive disorder and bipolar disorder. | Q38007965 | ||
| Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? | Q38022815 | ||
| Clinically significant drug interactions with atypical antipsychotics | Q38156416 | ||
| Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach | Q38169349 | ||
| The integrative management of treatment-resistant depression: a comprehensive review and perspectives | Q38181363 | ||
| Role of lithium augmentation in the management of major depressive disorder | Q38192967 | ||
| Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. | Q38207875 | ||
| Early switching strategies in antidepressant non-responders: current evidence and future research directions. | Q38211978 | ||
| Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis | Q38226055 | ||
| Ketamine administration in depressive disorders: a systematic review and meta-analysis | Q38231235 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| major depressive disorder | Q42844 | ||
| P304 | page(s) | 540-560 | |
| P577 | publication date | 2016-08-02 | |
| P1433 | published in | Canadian Journal of Psychiatry | Q5030253 |
| P1476 | title | Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments | |
| P478 | volume | 61 |
| Q92063862 | A Post-Authorization Safety Study of Quetiapine as Antidepressant Treatment in Sweden: Nested Case-Control Analyses of Select Outcomes |
| Q90985084 | A dramatic case of a woman discovered after 7 months of untreated catatonia |
| Q55185849 | A review of ketamine's role in ECT and non-ECT settings. |
| Q55334438 | Addictive potential of novel treatments for refractory depression and anxiety. |
| Q43259449 | Adjunctive Trazodone and Depression Outcome in Adolescents Treated with Serotonin Re-uptake Inhibitors |
| Q89611888 | An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report |
| Q88452394 | Anhedonia in depression and schizophrenia: A transdiagnostic challenge |
| Q64977750 | Antidepressant treatment and mortality risk in patients with dementia and depression: a nationwide population cohort study in Taiwan. |
| Q47285494 | Antidepressants and Mood Stabilizers: Novel Research Avenues and Clinical Insights for Bipolar Depression |
| Q57689353 | Antidepressants for the treatment of depression in people with cancer |
| Q47640531 | Antipsychotic Use With and Without Comorbid Psychiatric Diagnosis Among Adults with Intellectual and Developmental Disabilities |
| Q58573474 | Assessment and Management of Cognitive and Psychosocial Dysfunctions in Patients With Major Depressive Disorder: A Clinical Review |
| Q88788303 | Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD) |
| Q98830300 | Benefit-Risk Assessment of Esketamine Nasal Spray versus Placebo in Treatment-Resistant Depression |
| Q47651793 | Between a rock-a-bye and a hard place: mood disorders during the peripartum period |
| Q92218063 | Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis |
| Q92068650 | Canadian Medication Cost Savings Associated with Combinatorial Pharmacogenomic Guidance for Psychiatric Medications |
| Q37197207 | Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly. |
| Q92235652 | Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine |
| Q57053430 | Cerebellar Cortex as a Therapeutic Target for Neurostimulation |
| Q99709166 | Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depression-A Literature Review |
| Q37643035 | Clinical Practice Guidelines for the management of Depression |
| Q61805889 | Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental) |
| Q92909426 | Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental |
| Q64904022 | Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depression: protocol for a systematic review and networkmeta-analysis. |
| Q47553011 | Comparative efficacy and acceptability of interventions for major depression in older persons: protocol for Bayesian network meta-analysis |
| Q47201674 | Comparative efficacy and tolerability of new-generation antidepressants for major depressive disorder in children and adolescents: protocol of an individual patient data meta-analysis |
| Q92430456 | Complementary therapies for clinical depression: an overview of systematic reviews |
| Q89589038 | Cost-Utility Analysis of Mindfulness-Based Cognitive Therapy Versus Antidepressant Pharmacotherapy for Prevention of Depressive Relapse in a Canadian Context |
| Q64993527 | Cost-effectiveness of Electroconvulsive Therapy vs Pharmacotherapy/Psychotherapy for Treatment-Resistant Depression in the United States. |
| Q90638811 | Crossing Death Valley: Bringing Neurotechnology to Psychiatric Clinics in Alberta, Canada |
| Q92541885 | Depression in the Primary Care Setting. Reply |
| Q92584883 | Depression is a major risk factor for the development of dementia in people with lower urinary tract symptoms: A nationwide population-based study |
| Q52369980 | Drug-drug interactions involving antidepressants: focus on desvenlafaxine. |
| Q91470290 | Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report |
| Q92236771 | Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study |
| Q38374198 | Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial |
| Q31142701 | Effect of antipsychotic pharmacotherapy on clinical outcomes of intermittent theta-burst stimulation for refractory depression |
| Q92605568 | Effectiveness of mirtazapine as add-on to paroxetine v. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial |
| Q55364555 | Effects of a 12-week running programme in youth and adults with complex mood disorders. |
| Q91765499 | Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) |
| Q64103108 | Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity |
| Q64325124 | Efficacy of vortioxetine on the physical symptoms of major depressive disorder |
| Q98386641 | Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review |
| Q91650649 | Evaluating Prevalence and Patterns of Prescribing Medications for Depression for Patients With Obesity Using Large Primary Care Data (Canadian Primary Care Sentinel Surveillance Network) |
| Q47550497 | Fatigue in Patients with Major Depressive Disorder: Prevalence, Burden and Pharmacological Approaches to Management. |
| Q42369081 | From Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder |
| Q47599068 | Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient |
| Q47557944 | Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies |
| Q91522097 | GPR56/ADGRG1 is associated with response to antidepressant treatment |
| Q96305023 | Grant Report on SCH: Personalized Depression Treatment Supported by Mobile Sensor Analytics |
| Q90697443 | Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report |
| Q64930515 | Impact of a structured, group-based running programme on clinical, cognitive and social function in youth and adults with complex mood disorders: a 12-week pilot study. |
| Q92774277 | Improvement of psychiatrists' clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' project: A nation |
| Q93080822 | Indices of Change, Expectations, and Popularity of Biological Treatments for Major Depressive Disorder between 1988 and 2017: A Scientometric Analysis |
| Q90597788 | Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants |
| Q64866240 | Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors. |
| Q64232538 | Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment |
| Q40379672 | Italian patients with more recent onset of Major Depressive Disorder have a shorter duration of untreated illness. |
| Q90407228 | Ketamine for chronic depression: two cautionary tales |
| Q41474591 | Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines. |
| Q48514039 | Korean Medication Algorithm for Depressive Disorders 2017: Third Revision. |
| Q93015148 | Legacy Drug-Prescribing Patterns in Primary Care |
| Q50301186 | Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring. |
| Q96134207 | Malaysian macroalga Padina australis Hauck attenuates high dose corticosterone-mediated oxidative damage in PC12 cells mimicking the effects of depression |
| Q90284965 | Mental Health Service Utilization in Depressed Canadian Armed Forces Personnel |
| Q47604739 | Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement |
| Q64880287 | Multinational comparison of new antidepressant use in older adults: a cohort study. |
| Q52668973 | Neighbourhood Material and Social Deprivation and Exposure to Antidepressant Drug Treatment: A Cohort Study Using Administrative Data. |
| Q47651782 | New medications for treatment-resistant depression: a brief review of recent developments |
| Q47661902 | Off-label use of antipsychotics and associated factors in community living older adults |
| Q59813203 | Optimized regimens of combined medications for the treatment of major depressive disorder: a double-blind, randomized-controlled trial |
| Q52659318 | Patient perspectives on the role of community pharmacists for antidepressant treatment: A qualitative study. |
| Q90240601 | Personalized Psychiatry and Depression: The Role of Sociodemographic and Clinical Variables |
| Q92907278 | Pharmacogenetics and Depression: A Critical Perspective |
| Q47927842 | Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines |
| Q39177113 | Potential Use of MicroRNA for Monitoring Therapeutic Response to Antidepressants |
| Q47577352 | Potentially inappropriate prescription of antidepressants in old people: characteristics, associated factors, and impact on mortality |
| Q90428157 | Precision non-implantable neuromodulation therapies: a perspective for the depressed brain |
| Q91799302 | Predictors of functional response and remission with desvenlafaxine 50 mg and 100 mg: a pooled analysis of randomized, placebo-controlled studies in patients with major depressive disorder |
| Q90083342 | Prescribing happiness |
| Q90083344 | Prescrire le bonheur |
| Q92502335 | Protocol for studying racial/ethnic disparities in depression care using joint information from participant surveys and administrative claims databases: an observational cohort study |
| Q61635299 | Psychotherapy for Major Depressive Disorder and Generalized Anxiety Disorder: A Health Technology Assessment |
| Q41025993 | Recognition and management of antidepressant discontinuation syndrome |
| Q93123814 | Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder |
| Q55431520 | Rethinking the spectrum of mood disorders: implications for diagnosis and management – Proceedings of a symposium presented at the 30th Annual European College of Neuropsychopharmacology Congress, 4 September 2017, Paris, France. |
| Q57127981 | Role of Ginkgo biloba extract as an adjunctive treatment of elderly patients with depression and on the expression of serum S100B |
| Q97067263 | Safety and Tolerability of Both Arm Ischemic Conditioning in Patients With Major Depression: A Proof of Concept Study |
| Q98577206 | Self-microemulsifying drug delivery system (SMEDDS) of curcumin attenuates depression in olfactory bulbectomized rats |
| Q90286450 | Should antidepressants be used for major depressive disorder? |
| Q38619996 | Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder |
| Q95259468 | Stiff-person syndrome in a patient with comorbid bipolar and panic disorders: A case report and literature review |
| Q94544840 | Symptoms of Major Depressive Disorder and Their Impact on Psychosocial Functioning in the Different Phases of the Disease: Do the Perspectives of Patients and Healthcare Providers Differ? |
| Q55515658 | The Development of a Community Pharmacy-Based Intervention to Optimize Patients’ Use of and Experience with Antidepressants: A Step-by-Step Demonstration of the Intervention Mapping Process. |
| Q55113792 | The MAKE Biomarker Discovery for Enhancing anTidepressant Treatment Effect and Response Study: Design and Methodology. |
| Q49348800 | The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants |
| Q47141387 | The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone |
| Q98647362 | The therapeutic effects and safety of bright light therapy combined with escitalopram oxalate on insomnia in patients with poststroke depression |
| Q100736109 | Toward measuring effective treatment coverage: critical bottlenecks in quality- and user-adjusted coverage for major depressive disorder |
| Q57808859 | Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot Trial |
| Q95579830 | Treating psychiatric symptoms and disorders with non-psychotropic medications |
| Q61444891 | Twelve Chinese herbal preparations for the treatment of depression or depressive symptoms in cancer patients: a systematic review and meta-analysis of randomized controlled trials |
| Q47668646 | Unpacking Major Depressive Disorder: From Classification to Treatment Selection |
| Q42339068 | Updated CANMAT Guidelines for Treatment of Major Depressive Disorder |
| Q92216003 | miRNAs in depression vulnerability and resilience: novel targets for preventive strategies |
Search more.